Option chain shows key data for Cellebrite DI's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Cellebrite DI.

Cellebrite DI (NASDAQ:CLBT) Stock, Option Chain

Cellebrite DI

Cellebrite DI Ltd is an Israeli digital intelligence company that provides tools for federal, state, and local law enforcement as well as enterprise companies and service providers to collect, review, analyze and manage digital data. Some of its products include Cellebrite UFED, Cellebrite Physical Analyzer, Cellebrite UFED Cloud, Cellebrite Frontliner, Cellebrite Responder, Cellebrite Premium, and Cellebrite Seeker.

Movers

News

Intraday Update

Markets

Trading Ideas

AMBI

ASTS

BABA

CINT

CLBT

JMIA

PSNY

RKLB

SIGA

TMCI

H&amp;R Block Posts Upbeat Earnings, Joins Alibaba Group, CI&amp;T And Other Big Stocks Moving Higher On Friday

Trump Might Do Away With EV Mandates

Politics

Tech

General

Despite having a license for Cellebrite&#39;s software, the FBI&#39;s Pittsburgh bureau was unable to bypass the passcode on Crooks&#39; newer Samsung model phone, which runs on Android&#39;s operating system.

FBI Reportedly Used Israel-Based Security Firm&#39;s Unreleased Technology To Crack Trump Shooter&#39;s Phone

Double,Exposure,Of,Business,Man,Hand,Working,On,Blank,Screen

Earnings

Equities

Mid Cap

Guidance

IZRL

Cellebrite DI reported strong Q1 FY24 results with revenue up 26% YoY, ARR at $331.8 million, and EPS beating consensus. Outlook remains positive with expected revenue of $90M-$94M in Q2 and $370M-$380M for FY24.

Why Software Company Cellebrite Shares Are Up Today

Cellebrite DI Ltd

Atlassian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) reported quarterly earnings of $0.96 per share which beat the analyst consensus estimate of $0.76 by 26.32 percent. This is a 31.51 percent increase over earnings of $0.73 per share from the same period last year. The company reported quarterly sales of $1.29 billion which beat the analyst consensus estimate of $1.24 billion by 3.73 percent. This is a 21.32 percent increase over sales of $1.06 billion the same period last year.

Earnings Beats

TEAM

Atlassian Q2 2025 Adj EPS $0.96 Beats $0.76 Estimate, Sales $1.29B Beat $1.24B Estimate

Olin Sees Q1 adjusted EBITDA $150M-$170M.

WIIM

INTC

Intel shares are trading higher following better-than-expected Q4 financial results.

Allowed claims protect composition of matter and methods of use for EB-003, a neuroplastogen targeting undertreated mental health indications
Enveric Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVB#NASDAQ">ENVB</a>) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced that it has received a Notice of Allowance (NOA) from the United States Patent and Trademark Office (USPTO) for a patent application pertaining to its EVM301 Series of molecules being developed as potential treatments for mental health disorders.
The USPTO issues a Notice of Allowance after making the determination that a patent should be granted from an application.

Biotech

ENVB

Enveric Biosciences Receives Notice Of Allowance For Lead Drug Candidate EB-003 From U.S. Patent And Trademark Office

AppFolio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APPF#NASDAQ">APPF</a>) sees FY2025 sales of $920.000 million-940.000 million vs $927.31 million estimate.

APPF

AppFolio Sees FY2025 Sales $920.000M-940.000M vs $927.31M Est

Visa Q1 Payment Volume Up 9%, Cross-Border Volume Total Up 16%, Processed Transactions Up 11%

AppFolio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APPF#NASDAQ">APPF</a>) reported quarterly earnings of $0.92 per share which missed the analyst consensus estimate of $0.94 by 2.13 percent. This is a 4.55 percent increase over earnings of $0.88 per share from the same period last year. The company reported quarterly sales of $203.66 million which beat the analyst consensus estimate of $200.00 million by 1.83 percent. This is a 18.53 percent increase over sales of $171.83 million the same period last year.

Earnings Misses

AppFolio Q4 Adj $0.92 Misses $0.94 Estimate, Sales $203.66M Beat $200.00M Estimate

Gen Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEN#NASDAQ">GEN</a>) reported quarterly earnings of $0.56 per share which beat the analyst consensus estimate of $0.55 by 1.82 percent. This is a 14.29 percent increase over earnings of $0.49 per share from the same period last year. The company reported quarterly sales of $986.00 million which beat the analyst consensus estimate of $985.08 million by 0.09 percent. This is a 3.68 percent increase over sales of $951.00 million the same period last year.

Gen Digital Q3 2025 Adj EPS $0.56 Beats $0.55 Estimate, Sales $986.00M Beat $985.08M Estimate

KLA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLAC#NASDAQ">KLAC</a>) reported quarterly earnings of $8.20 per share which beat the analyst consensus estimate of $7.75 by 5.81 percent. This is a 33.12 percent increase over earnings of $6.16 per share from the same period last year. The company reported quarterly sales of $3.08 billion which beat the analyst consensus estimate of $2.94 billion by 4.71 percent. This is a 23.72 percent increase over sales of $2.49 billion the same period last year.

KLAC

KLA Q2 2025 Adj EPS $8.20 Beats $7.75 Estimate, Sales $3.08B Beat $2.94B Estimate

First Business Finl Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBIZ#NASDAQ">FBIZ</a>) reported quarterly earnings of $1.43 per share which beat the analyst consensus estimate of $1.27 by 12.6 percent. This is a 24.35 percent increase over earnings of $1.15 per share from the same period last year. The company reported quarterly sales of $41.15 million which beat the analyst consensus estimate of $39.30 million by 4.72 percent. This is a 12.34 percent increase over sales of $36.63 million the same period last year.

FBIZ

First Business Finl Servs Q4 Adj EPS $1.43 Beats $1.27 Estimate, Sales $41.15M Beat $39.30M Estimate

Visa (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) reported quarterly earnings of $2.75 per share which beat the analyst consensus estimate of $2.66 by 3.38 percent. This is a 14.11 percent increase over earnings of $2.41 per share from the same period last year. The company reported quarterly sales of $9.510 billion which beat the analyst consensus estimate of $9.341 billion by 1.81 percent. This is a 10.15 percent increase over sales of $8.634 billion the same period last year.

Visa Q1 2025 Adj. EPS $2.75 Beats $2.66 Estimate, Sales $9.510B Beat $9.341B Estimate

<h3>Gainers</h3>
<ul>
<li>MGO Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGOL#NASDAQ">MGOL</a>) shares increased by 31.9% to $0.13 during Thursday's pre-market session. The company's market cap stands at $1.2 million. </li>
<li>Sacks Parente Golf (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPGC#NASDAQ">SPGC</a>) shares increased by 30.5% to $0.77. The market value of their outstanding shares is at $6.7 million. </li>
<li>Jinxin Technology Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAMI#NASDAQ">NAMI</a>) stock increased by 12.26% to $2.93. The market value of their outstanding shares is at $187.6 million. </li>
<li>Nova Lifestyle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVFY#NASDAQ">NVFY</a>) stock increased by 10.16% to $0.65. The company's market cap stands at $4.6 million. </li>
<li>Las Vegas Sands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LVS#NYSE">LVS</a>) stock moved upwards by 9.5% to $47.56. The market value of their outstanding shares is at $34.4 billion. As per the news, the Q4 earnings report came out yesterday. </li>
<li>Bassett Furniture Indus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSET#NASDAQ">BSET</a>) shares rose 8.87% to $15.45. The company's market cap stands at $135.9 million. As per the press release, Q4 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>China Liberal Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLEU#NASDAQ">CLEU</a>) stock fell 86.8% to $1.02 during Thursday's pre-market session. The market value of their outstanding shares is at $274.7 million. </li>
<li>FAT Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FAT#NASDAQ">FAT</a>) shares fell 38.68% to $3.6. The company's market cap stands at $61.2 million. </li>
<li>FAT Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FATBB#NASDAQ">FATBB</a>) stock declined by 29.14% to $5.01. The company's market cap stands at $85.2 million. </li>
<li>Culp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CULP#NYSE">CULP</a>) shares decreased by 25.93% to $4.0. The company's market cap stands at $50.2 million. </li>
<li>1-800-Flowers.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLWS#NASDAQ">FLWS</a>) stock decreased by 19.26% to $7.13. The market value of their outstanding shares is at $455.2 million. As per the press release, Q2 earnings came out today. </li>
<li>Envirotech Vehicles (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVTV#NASDAQ">EVTV</a>) shares fell 17.46% to $0.55. The company's market cap stands at $8.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BSET

CLEU

CULP

EVTV

FATBB

FLWS

MGOL

NAMI

NVFY

SPGC

12 Consumer Discretionary Stocks Moving In Thursday's Pre-Market Session

Olin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OLN#NYSE">OLN</a>) reported quarterly earnings of $0.09 per share which beat the analyst consensus estimate of $(0.03) by 400 percent. This is a 79.07 percent decrease over earnings of $0.43 per share from the same period last year. The company reported quarterly sales of $1.671 which missed the analyst consensus estimate of $1.549 billion by 100.00 percent. This is a 100.00 percent decrease over sales of $1.615 billion the same period last year.

Olin Q4 2024 GAAP EPS $0.09 Beats $(0.03) Estimate, Sales $1.671 Miss $1.549B Estimate

<h3>Gainers</h3>
<ul>
<li>Alterity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHE#NASDAQ">ATHE</a>) shares moved upwards by 95.9% to $5.7 during Thursday's pre-market session. The market value of their outstanding shares is at $49.8 million. </li>
<li>Tectonic Therapeutic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECX#NASDAQ">TECX</a>) stock rose 92.37% to $49.48. The company's market cap stands at $729.9 million. </li>
<li>Kazia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KZIA#NASDAQ">KZIA</a>) stock increased by 54.34% to $2.13. The market value of their outstanding shares is at $11.9 million. </li>
<li>NanoVibronix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAOV#NASDAQ">NAOV</a>) stock rose 42.79% to $0.55. The company's market cap stands at $3.3 million. </li>
<li>Processa Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCSA#NASDAQ">PCSA</a>) stock rose 18.41% to $0.7. The company's market cap stands at $2.5 million. </li>
<li>Concord Medical Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCM#NYSE">CCM</a>) shares increased by 15.2% to $5.0. The market value of their outstanding shares is at $217.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Cargo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRGX#NASDAQ">CRGX</a>) shares decreased by 76.6% to $3.09 during Thursday's pre-market session. The market value of their outstanding shares is at $142.2 million. </li>
<li>Silexion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) shares declined by 27.39% to $2.28. The company's market cap stands at $9.1 million. </li>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) shares fell 26.21% to $0.07. The market value of their outstanding shares is at $1.1 million. </li>
<li>Evaxion Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVAX#NASDAQ">EVAX</a>) stock declined by 25.08% to $2.54. The market value of their outstanding shares is at $5.7 million. </li>
<li>Inhibikase Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IKT#NASDAQ">IKT</a>) shares decreased by 21.06% to $2.21. The market value of their outstanding shares is at $153.3 million. </li>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) stock declined by 14.15% to $1.7. The company's market cap stands at $19.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Alterity Therapeutics Limited - American Depositary Shares

ATHE

CRGX

EVAX

GCTK

KZIA

NAOV

PCSA

SLXN

TECX

12 Health Care Stocks Moving In Thursday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Alpha Modus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMOD#NASDAQ">AMOD</a>) shares moved upwards by 77.3% to $2.73 during Thursday's pre-market session. The market value of their outstanding shares is at $36.0 million. </li>
<li>ScanTech AI Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAI#NASDAQ">STAI</a>) shares rose 24.0% to $1.86. The market value of their outstanding shares is at $34.8 million. </li>
<li>Banzai International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNZI#NASDAQ">BNZI</a>) shares moved upwards by 21.76% to $2.35. The market value of their outstanding shares is at $20.2 million. </li>
<li>Celestica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>) stock increased by 18.32% to $118.9. The company's market cap stands at $13.8 billion. The company's, Q4 earnings came out yesterday. </li>
<li>NetScout Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTCT#NASDAQ">NTCT</a>) stock increased by 16.37% to $26.01. The company's market cap stands at $1.8 billion. As per the press release, Q3 earnings came out today. </li>
<li>Coda Octopus Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CODA#NASDAQ">CODA</a>) stock rose 12.1% to $8.8. The market value of their outstanding shares is at $98.5 million. As per the press release, Q4 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Saverone 2014 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVRE#NASDAQ">SVRE</a>) shares fell 22.5% to $0.62 during Thursday's pre-market session. The market value of their outstanding shares is at $3.0 million. </li>
<li>Signing Day Sports (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SGN#AMEX">SGN</a>) stock declined by 16.83% to $3.61. The company's market cap stands at $2.0 million. </li>
<li>Teradyne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>) stock decreased by 16.43% to $102.0. The company's market cap stands at $16.6 billion. As per the press release, Q4 earnings came out yesterday. </li>
<li>Diginex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGNX#NASDAQ">DGNX</a>) shares fell 14.58% to $42.84. The market value of their outstanding shares is at $985.0 million. </li>
<li>ServiceNow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>) stock fell 10.48% to $1023.79. The market value of their outstanding shares is at $211.2 billion. The company's, Q4 earnings came out yesterday. </li>
<li>Ostin Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OST#NASDAQ">OST</a>) stock decreased by 9.56% to $2.65. The company's market cap stands at $4.9 million. As per the press release, FY earnings came out 3 days ago. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMOD

BNZI

CODA

DGNX

NTCT

STAI

SVRE

12 Information Technology Stocks Moving In Thursday's Pre-Market Session

Chief Executive Officer Dr. Ryan Ezell commented, "We look forward to reporting our fourth quarter results, which we currently expect will be the strongest in terms of net income and adjusted EBITDA (1) as compared to the previously reported quarterly results for 2024. &nbsp;Our continued financial and operational improvements reflect the considerable effort put forth by our employee group and the execution of our corporate strategy towards the convergence of innovative data and chemical solutions."&nbsp;
The Company plans to issue its fourth quarter and full-year 2024 financial and operating results press release after market close on Monday, March 10, 2025, and host its earnings conference call on Tuesday, March 11, 2025, at 9:00 a.m. CST (10:00 a.m. EST).

Flotek Industries CEO Ryan Ezell Says "We Look Forward To Reporting Our Q4 Results, Which We Currently Expect Will Be The Strongest In Terms Of Net Income And Adjusted EBITDA As Compared To The Previously Reported Quarterly Results For 2024. Our Continued Financial And Operational Improvements Reflect The Considerable Effort Put Forth By Our Employee Group And The Execution Of Our Corporate Strategy Towards The Convergence Of Innovative Data And Chemical Solutions."

Deckers Outdoor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>) reported quarterly earnings of $3.00 per share which beat the analyst consensus estimate of $2.55 by 17.65 percent. This is a 19.05 percent increase over earnings of $2.52 per share from the same period last year. The company reported quarterly sales of $1.83 billion which beat the analyst consensus estimate of $1.73 billion by 5.57 percent. This is a 17.12 percent increase over sales of $1.56 billion the same period last year.

DECK

Deckers Outdoor Q3 2025 GAAP EPS $3.00 Beats $2.55 Estimate, Sales $1.83B Beat $1.73B Estimate

ResMed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>) reported quarterly earnings of $2.43 per share which beat the analyst consensus estimate of $2.32 by 4.74 percent. This is a 29.26 percent increase over earnings of $1.88 per share from the same period last year. The company reported quarterly sales of $1.28 billion which beat the analyst consensus estimate of $1.27 billion by 1.15 percent. This is a 10.23 percent increase over sales of $1.16 billion the same period last year.

ResMed Q2 2025 Adj EPS $2.43 Beats $2.32 Estimate, Sales $1.28B Beat $1.27B Estimate

Cavco Indus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVCO#NASDAQ">CVCO</a>) reported quarterly earnings of $6.90 per share which beat the analyst consensus estimate of $4.89 by 41.1 percent. This is a 61.59 percent increase over earnings of $4.27 per share from the same period last year. The company reported quarterly sales of $522.04 million which beat the analyst consensus estimate of $480.31 million by 8.69 percent. This is a 16.85 percent increase over sales of $446.77 million the same period last year.

CVCO

Cavco Indus Q3 EPS $6.90 Beats $4.89 Estimate, Sales $522.04M Beat $480.31M Estimate

The Q4 earnings report for SkyWest (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYW#NASDAQ">SKYW</a>) was released on Thursday, January 30, 2025 at 04:01 PM.
Here's what investors need to know about the latest announcement.
<h3>Earnings</h3>
SkyWest beat estimated earnings by 28.999999999999996%, reporting an EPS of $2.34 versus an estimate of $1.81.
Revenue was up $192.62 million from the same period last year.
<h3>Earnings History Overview</h3>
During the previous quarter, the company beat on EPS by $0.24, leading to a 6.0% increase share price change the next day.
Here's a look at SkyWest's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.92</td>
<td>1.73</td>
<td>1.23</td>
<td>0.15</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>2.16</td>
<td>1.82</td>
<td>1.45</td>
<td>0.42</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>889.00M</td>
<td>826.62M</td>
<td>800.15M</td>
<td>758.49M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>912.79M</td>
<td>867.12M</td>
<td>803.61M</td>
<td>751.79M</td>
</tr>
</tbody>
</table>

To track all earnings releases for SkyWest <a href="https://www.benzinga.com/quote/SKYW/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SKYW

SkyWest Earnings Review: Q4 Summary

Press Releases

Cellebrite to Report Third-Quarter 2024 Financial Results on November 6, 2024

Cellebrite Announces Tim Tebow as Keynote Speaker for Inaugural Case-to-Closure (C2C) User Summit 2025

CORRECTION: Cellebrite Announces Third-Quarter 2024 Results

Management

Yossi Carmil to Step Down as CEO After Nearly 20 Years

Cellebrite and Relativity Deliver Solutions to Transform the Mobile Data Collection Landscape

Cellebrite Announces Participation in the UBS Global Technology and AI Conference

D-Fend Solutions Raises $31M to Fortify Cyber Counter-Drone Technology and Market Leadership

Cellebrite Appoints Michael D. Capellas to Board of Directors as Lead Independent Director

Cellebrite Announces Participation in the 27th Annual Needham & Company Growth Conference

Cellebrite to Report Fourth-Quarter and Fiscal Year 2024 Financial Results on February 13, 2025

Comments

Cellebrite DI

Cellebrite DI (CLBT) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga